Benefit of transaminase elevations in establishing functional cure of HBV infection during nap‐based combination therapy
| Autor: | Liviu Iarovoi, Adalbert Krawczyk, Alina Jucov, Lilia Cojuhari, Ulf Dittmer, Valentin Cebotarescu, Iurie Moscalu, Victor Pântea, Pavlina Jimbei, Michel Bazinet, Andrew Vaillant, Valentina Smeşnoi, Gheorghe Plăcintă, Tatiana Musteata |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Viral rebound
Hepatitis B virus HBsAg medicine.medical_specialty Combination therapy Medizin Antiviral Agents Gastroenterology Transaminase 03 medical and health sciences 0302 clinical medicine Immunity Virology Internal medicine Humans Medicine 030212 general & internal medicine Transaminases Retrospective Studies Hepatitis B Surface Antigens Hepatology business.industry virus diseases Alanine Transaminase digestive system diseases Nap Infectious Diseases DNA Viral 030211 gastroenterology & hepatology business |
| Zdroj: | Journal of Viral Hepatitis. 28:817-825 |
| ISSN: | 1365-2893 1352-0504 |
| DOI: | 10.1111/jvh.13483 |
| Popis: | Treatment of HBV infection with nucleic acid polymers and pegIFN is accompanied by transaminase elevations in 95% of participants. HBV viral rebound, partial cure (HBV DNA 2000 IU/mL, normal ALT) or functional cure (HBV DNA target not detected, HBsAgLLOQ, normal ALT) occurred in 27%, 38% and 35% of participants. Correlations between ALT, AST and GGT elevations, virologic baseline, response during therapy and HBV therapeutic outcome were investigated. A retrospective analysis of all 40 participants in the REP 401 study (NCT02565719) included maxima and area under the curve for ALT, AST and GGT, baseline virology, HBsAg and anti-HBs response and HBV therapeutic outcomes. ALT, AST and GGT elevations were asymptomatic, independent of baseline virologic status and anti-HBs response but correlated with HBsAg reduction ≥3 log |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|